Shares in Ultragenyx weakened after a midpipeline drug candidate missed its targets in a trial for a rare genetic disorder.

Tessa Therapeutics has bought Euchloe Bio for its suite of checkpoint inhibitors.

The FDA approved Medtronic’s latest iteration of its CoreValve Evolut TAVR for patients who are too frail for open-heart surgery.

Former FDA commissioner Robert Califf, who was not asked back into his role by President Donald Trump, has become the new chair of the newly formed People-…

Novartis’ phase 3 trial of serelaxin in acute heart failure has missed its primary endpoint.

Last year, Cardiff, U.K.-based Verona secured £44.7 million ($65.6 million) from big-name investors on both sides of the Atlantic for work on its PDE3/PDE4…

Neurocrine Biosciences has published a journal paper about its phase 3 trial of tardive dyskinesia candidate Ingrezza.

Shares in Cerulean Pharma nosedived yesterday after the company agreed to sell off its anticancer assets at a bargain basement price and merge with Daré…